AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat.